|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Early Breast Cancer Trialists’
Collaborative Group. Davies C, Godwin J, et al: Relevance of breast
cancer hormone receptors and other factors to the efficacy of
adjuvant tamoxifen: patient-level meta-analysis of randomised
trials. Lancet. 378:771–784. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Early Breast Cancer Trialists’
Collaborative Group. Peto R, Davies C, et al: Comparisons between
different polychemotherapy regimens for early breast cancer:
meta-analyses of long-term outcome among 100,000 women in 123
randomised trials. Lancet. 379:432–444. 2012. View Article : Google Scholar
|
|
4
|
Gianni L, Dafni U, Gelber RD, et al:
Treatment with trastuzumab for 1 year after adjuvant chemotherapy
in patients with HER2-positive early breast cancer: a 4-year
follow-up of a randomised controlled trial. Lancet Oncol.
12:236–244. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cortazar P, Zhang L, Untch M, et al:
Pathological complete response and long-term clinical benefit in
breast cancer: the CTNeoBC pooled analysis. Lancet. 384:164–172.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cancer Genome Atlas Network. Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Turner NC and Reis-Filho JS: Tackling the
diversity of triple-negative breast cancer. Clin Cancer Res.
19:6380–6388. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cancer Genome Atlas Research Network.
Kandoth C, Schultz N, et al: Integrated genomic characterization of
endometrial carcinoma. Nature. 497:67–73. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rescher U and Gerke V: Annexins - unique
membrane binding proteins with diverse functions. J Cell Sci.
117:2631–2639. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Parente L and Solito E: Annexin 1: more
than an anti-phospholipase protein. Inflamm Res. 53:125–132. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lim LH and Pervaiz S: Annexin 1: the new
face of an old molecule. FASEB J. 21:968–975. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Garcia Pedrero JM, Fernandez MP, Morgan
RO, et al: Annexin A1 down-regulation in head and neck cancer is
associated with epithelial differentiation status. Am J Pathol.
164:73–79. 2004. View Article : Google Scholar
|
|
13
|
Luo A, Kong J, Hu G, et al: Discovery of
Ca2+-relevant and differentiation-associated genes
downregulated in esophageal squamous cell carcinoma using cDNA
microarray. Oncogene. 23:1291–1299. 2004. View Article : Google Scholar
|
|
14
|
Sinha P, Hütter G, Köttgen E, Dietel M,
Schadendorf D and Lage H: Increased expression of annexin I and
thioredoxin detected by two-dimensional gel electrophoresis of drug
resistant human stomach cancer cells. J Biochem Biophys Methods.
37:105–116. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Duncan R, Carpenter B, Main LC, Telfer C
and Murray GI: Characterisation and protein expression profiling of
annexins in colorectal cancer. Br J Cancer. 98:426–433. 2008.
View Article : Google Scholar
|
|
16
|
Sato Y, Kumamoto K, Saito K, et al:
Up-regulated Annexin A1 expression in gastrointestinal cancer is
associated with cancer invasion and lymph node metastasis. Exp Ther
Med. 2:239–243. 2011.PubMed/NCBI
|
|
17
|
Bai XF, Ni XG, Zhao P, et al:
Overexpression of annexin 1 in pancreatic cancer and its clinical
significance. World J Gastroenterol. 10:1466–1470. 2004.PubMed/NCBI
|
|
18
|
Masaki T, Tokuda M, Ohnishi M, et al:
Enhanced expression of the protein kinase substrate annexin in
human hepatocellular carcinoma. Hepatology. 24:72–81.
1996.PubMed/NCBI
|
|
19
|
Kang JS, Calvo BF, Maygarden SJ, Caskey
LS, Mohler JL and Ornstein DK: Dysregulation of annexin I protein
expression in high-grade prostatic intraepithelial neoplasia and
prostate cancer. Clin Cancer Res. 8:117–123. 2002.PubMed/NCBI
|
|
20
|
Pencil SD and Toth M: Elevated levels of
annexin I protein in vitro and in vivo in rat and human mammary
adenocarcinoma. Clin Exp Metastasis. 16:113–121. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ahn SH, Sawada H, Ro JY and Nicolson GL:
Differential expression of annexin I in human mammary ductal
epithelial cells in normal and benign and malignant breast tissues.
Clin Exp Metastasis. 15:151–156. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang LP, Bi J, Yao C, et al: Annexin A1
expression and its prognostic significance in human breast cancer.
Neoplasma. 57:253–259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shen D, Chang HR, Chen Z, et al: Loss of
annexin A1 expression in human breast cancer detected by multiple
high-throughput analyses. Biochem Biophys Res Commun. 326:218–227.
2005. View Article : Google Scholar
|
|
24
|
Shen D, Nooraie F, Elshimali Y, et al:
Decreased expression of annexin A1 is correlated with breast cancer
development and progression as determined by a tissue microarray
analysis. Hum Pathol. 37:1583–1591. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cao Y, Li Y, Edelweiss M, et al: Loss of
annexin A1 expression in breast cancer progression. Appl
Immunohistochem Mol Morphol. 16:530–534. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bist P, Leow SC, Phua QH, et al: Annexin-1
interacts with NEMO and RIP1 to constitutively activate IKK complex
and NF-κB: implication in breast cancer metastasis. Oncogene.
30:3174–3185. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
de Graauw M, van Miltenburg MH, Schmidt
MK, et al: Annexin A1 regulates TGF-beta signaling and promotes
metastasis formation of basal-like breast cancer cells. Proc Natl
Acad Sci USA. 107:6340–6345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Saito M, Matsuzaki M, Sakuma T, et al:
Clinicopathological study of non-palpable familial breast cancer
detected by screening mammography and diagnosed as DCIS. Breast
Cancer. 21:140–145. 2014. View Article : Google Scholar
|
|
29
|
Saito M, Shiraishi K, Matsumoto K, et al:
A three-microRNA signature predicts responses to platinum-based
doublet chemotherapy in patients with lung adenocarcinoma. Clin
Cancer Res. 20:4784–4793. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mastro AM and Vogler EA: A
three-dimensional osteogenic tissue model for the study of
metastatic tumor cell interactions with bone. Cancer Res.
69:4097–4100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nicolson GL, Nawa A, Toh Y, Taniguchi S,
Nishimori K and Moustafa A: Tumor metastasis-associated human MTA1
gene and its MTA1 protein product: role in epithelial cancer cell
invasion, proliferation and nuclear regulation. Clin Exp
Metastasis. 20:19–24. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen WT, Lee CC, Goldstein L, et al:
Membrane proteases as potential diagnostic and therapeutic targets
for breast malignancy. Breast Cancer Res Treat. 31:217–226. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Y, Serfass L, Roy MO, Wong J, Bonneau
AM and Georges E: Annexin-I expression modulates drug resistance in
tumor cells. Biochem Biophys Res Commun. 314:565–570. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chuthapisith S, Bean BE, Cowley G, et al:
Annexins in human breast cancer: Possible predictors of
pathological response to neoadjuvant chemotherapy. Eur J Cancer.
45:1274–1281. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gardner LB, Li Q, Park MS, Flanagan WM,
Semenza GL and Dang CV: Hypoxia inhibits G1/S transition through
regulation of p27 expression. J Biol Chem. 276:7919–7926. 2001.
View Article : Google Scholar
|
|
37
|
Giatromanolaki A, Koukourakis MI, Sivridis
E, et al: Relation of hypoxia inducible factor 1 alpha and 2 alpha
in operable non-small cell lung cancer to angiogenic/molecular
profile of tumours and survival. Br J Cancer. 85:881–890. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu L, Ning X, Sun L, et al:
Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced
chemoresistance in gastric cancer. Cancer Sci. 99:121–128.
2008.
|
|
39
|
Schindl M, Schoppmann SF, Samonigg H, et
al: Overexpression of hypoxia-inducible factor 1alpha is associated
with an unfavorable prognosis in lymph node-positive breast cancer.
Clin Cancer Res. 8:1831–1837. 2002.PubMed/NCBI
|
|
40
|
Welsh SJ, Bellamy WT, Briehl MM and Powis
G: The redox protein thioredoxin-1 (Trx-1) increases
hypoxia-inducible factor 1alpha protein expression: Trx-1
overexpression results in increased vascular endothelial growth
factor production and enhanced tumor angiogenesis. Cancer Res.
62:5089–5095. 2002.PubMed/NCBI
|
|
41
|
Keith B, Johnson RS and Simon MC: HIF1α
and HIF2α: sibling rivalry in hypoxic tumour growth and
progression. Nat Rev Cancer. 12:9–22. 2012.
|
